Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Reza-Thierry Elaidi"'
Autor:
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stéphane Oudard
Publikováno v:
Cancers, Vol 14, Iss 3, p 815 (2022)
Background: In metastatic prostate cancer (PCa) patients, androgen-deprivation therapy (ADT) combined with chemotherapy or next-generation androgen receptor targeted agents is a new standard treatment. The objective of the present study is to assess
Externí odkaz:
https://doaj.org/article/8d2e59e787c24d5fadfdb22a3210f95e
Autor:
Shervine Sharifzadehgan, Charlotte Ngo, Vincent Balaya, Hélène Bonsang-Kitzis, Reza-Thierry Elaidi, Stéphane Oudard, Fabrice Lecuru, Cynthia Lecurieux-Lafayette, Dominique Rousseau, Houda Belhouari, Laurence Crouillebois
Publikováno v:
The Breast Journal. 26:2357-2363
Introduction Detection of sentinel lymph node in early breast cancer is commonly based on the combination of patent blue dye and a radioisotope 99m Technetium. Each of these two tracers has advantages and disadvantages leading to the development of t
Autor:
Annelies Verbiest, Patrick Schöffski, Jessica Zucman-Rossi, Gabrielle Couchy, Stefano Caruso, Agnieszka Wozniak, Laurence Albiges, Wolf-Hervé Fridman, Nathalie Rioux-Leclercq, Reza-Thierry Elaidi, Maarten Albersen, Catherine Sautès-Fridman, Benoit Beuselinck, Stéphane Oudard, Inne Renders, Virginie Verkarre, Sylvie Job, Annouschka Laenen, Yann Vano, Evelyne Lerut
Publikováno v:
Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, Elsevier, 2019, 17 (5), pp.e981-e994. ⟨10.1016/j.clgc.2019.05.009⟩
Clinical Genitourinary Cancer, 2019, 17 (5), pp.e981-e994. ⟨10.1016/j.clgc.2019.05.009⟩
Clinical Genitourinary Cancer, Elsevier, 2019, 17 (5), pp.e981-e994. ⟨10.1016/j.clgc.2019.05.009⟩
Clinical Genitourinary Cancer, 2019, 17 (5), pp.e981-e994. ⟨10.1016/j.clgc.2019.05.009⟩
INTRODUCTION: Recent trials have suggested predictive biomarkers in advanced clear-cell renal cell carcinoma (accRCC): International Metastatic RCC Database Consortium (IMDC) good risk or angiogenic gene signature for sunitinib and IMDC intermediate/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6dac2d13ea1013fedbdc6b96d2acfc
https://hal.archives-ouvertes.fr/hal-02454456
https://hal.archives-ouvertes.fr/hal-02454456
Autor:
Gwenaelle Gravis, Aline Guillot, Christophe Massard, Thibault De La Motte Rouge, Florence Mercier, Nicolas Delanoy, Karim Fizazi, Reza-Thierry Elaidi, Stéphane Oudard, Aude Flechon, Antoine Angelergues, Philippe Beuzeboc, Sylvestre Le Moulec, Mustafa Ozguroglu, Denis Maillet
Publikováno v:
European Journal of Cancer. 50:1602-1609
A prostate-specific antigen (PSA) flare occurs in about 15% of metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel. This flare has no standard definition. Its impact on treatment efficacy is unclear. We sought to eval
Autor:
Reza-Thierry Elaidi, Stéphane Oudard
Publikováno v:
Cancer Treatment Reviews. 38:981-987
Multiple targeted agents are now available for the treatment of patients with metastatic renal cell carcinoma (mRCC). Although targeted agents offer improvements over previous treatments and significantly prolong progression-free survival, most patie
Autor:
A. Caty, Stéphane Oudard, Mustafa Ozguroglu, Reza-Thierry Elaidi, Marie Auvray, C. Dujardin, S. Guven, H. Gauthier, Eric Tartour, Stéphane Culine, Edouard Auclin
Publikováno v:
European Journal of Cancer. 51:S515-S516
Autor:
Florian Scotté, D.K. Duong, Reza-Thierry Elaidi, A. Bouchouicha, Stéphane Oudard, Constance Thibault, Bastien Rance
Publikováno v:
European Journal of Cancer. 51:S241-S242
Autor:
Florian Scotté, Reza-Thierry Elaidi, P. Combe, Antoine Angelergues, Constance Thibault, Elizabeth Fabre, Jacques Medioni, Stéphane Oudard
Publikováno v:
European Journal of Cancer. 51:S226-S227
Autor:
Jorge Aylllon, Florian Scotté, Reza-Thierry Elaidi, Stéphane Oudard, Jacques Medioni, José Balcaceres, Eduardo Barrascourt
Publikováno v:
Expert review of anticancer therapy. 9(6)
The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffectiv
Autor:
Laure Fournier, Reza-Thierry Elaidi, M. Bouaboula, A. Grine, Helena Pereira, A.S. Gille, L. Mauge, Eric Tartour, Stéphane Oudard, D. Helley
Publikováno v:
European Journal of Cancer. 51:S34